文献速递血栓与止血

评估 efanesoctocog alfa 单次静脉注射在2N型或3型血管性血友病成人中的药代动力学、安全性和耐受性的1期开放标签研究

A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease.
PubMed 文献 · J Thromb Haemost · 2025-07-18

这项1期开放标签研究纳入6例遗传性2N型(n=2)或3型(n=4)血管性血友病成人,单次静脉给予efanesoctocog alfa 25 IU/kg,评估药代动力学、安全性和耐受性。结果显示给药后FVIII活性>1 IU/dL可维持至10天,捕获显色法测得基线校正FVIII活性>40和>10 IU/dL分别维持至1天和4天,平均t1/2z为49.0小时,耐受良好,未检出FVIII抑制物或抗药抗体。

要点

  • 2N型或3型血管性血友病成人单次静脉给予efanesoctocog alfa 25 IU/kg后,FVIII活性>1 IU/dL维持至给药后10天。
  • 捕获显色法测得基线校正FVIII活性>40和>10 IU/dL分别维持至给药后1天和4天。
  • 平均(标准差)t1/2z为49.0(10.2)小时,耐受良好,未检出FVIII抑制物或抗药抗体。

核心结论

  • Efanesoctocog alfa耐受良好,并在2N型或3型血管性血友病患者中维持高FVIII活性水平达较长时间。

研究设计与样本

  • 1期开放标签研究(NCT04770935),纳入遗传性2N型或3型血管性血友病成人,单次静脉给予efanesoctocog alfa 25 IU/kg,共6例接受评估(2N型n=2;3型n=4)。

主要发现

  • 单次给予efanesoctocog alfa 25 IU/kg后,FVIII活性>1 IU/dL维持至给药后10天。
  • 按捕获显色法,基线校正FVIII活性平均值>40和>10 IU/dL分别维持至给药后1天和4天。
  • 平均(标准差)t1/2z为49.0(10.2)小时。
  • Efanesoctocog alfa耐受良好,未检出FVIII抑制物或抗药抗体。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efanesoctocog alfa is a high-sustained factor (F)VIII replacement therapy for hemophilia A. The D'D3 domain of efanesoctocog alfa overcomes the von Willebrand factor-imposed half-life ceiling and may allow correction of reduced FVIII levels experienced by people with type 2N or type 3 von Willebrand disease (VWD). OBJECTIVES: This study aimed to assess the pharmacokinetics, safety, and tolerability of efanesoctocog alfa in type 2N or type 3 VWD. METHODS: This was a phase 1, open-label study of efanesoctocog alfa in adults with hereditary type 2N or type 3 VWD (NCT04770935). Participants received a single intravenous dose of efanesoctocog alfa (25 IU/kg). The primary end point was pharmacokinetic parameters as determined by noncompartmental analysis of efanesoctocog alfa FVIII activity using one-stage assay and capture chromogenic assay, the latter of which is more relevant in assessing FVIII levels from efanesoctocog alfa among people with VWD. Secondary end points included adverse events and FVIII inhibitor development. RESULTS: Six participants were assessed (type 2N, n = 2; type 3, n = 4). One dose of efanesoctocog alfa of 25 IU/kg maintained FVIII activity levels of >1 IU/dL up to 10 days postdose. Mean baseline-corrected FVIII activity levels were maintained at >40 and >10 IU/dL up to 1 day and 4 days postdose, respectively, per capture chromogenic assay. Mean (standard deviation) t1/2z was 49.0 (10.2) hours. Efanesoctocog alfa was well tolerated. FVIII inhibitors or antidrug antibodies were not detected. CONCLUSION: Efanesoctocog alfa is well-tolerated and maintains high FVIII activity levels for a prolonged period in patients with type 2N or type 3 VWD.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Susen S, Trossaërt M, Zilberstein M, et al. A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease. J Thromb Haemost. 2025. PMID: 40685140. doi:10.1016/j.jtha.2025.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。